SENSITITRE 18-24 HOUR SUSCEPTIBILITY PLATES WITH TROVAFLOXACIN

K983301 · Accumed Intl., Inc. · JWY · Nov 25, 1998 · Microbiology

Device Facts

• Record ID: K983301
• Device Name: SENSITITRE 18-24 HOUR SUSCEPTIBILITY PLATES WITH TROVAFLOXACIN
• Applicant: Accumed Intl., Inc.
• Product Code: JWY · Microbiology
• Decision Date: Nov 25, 1998
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 866.1640
• Device Class: Class 2

Intended Use

The Sensititre 18 hour MIC or Breakpoint Susceptibility system is an in vitro diagnostic product for clinical susceptibility testing of gram negative and gram positive organisms. This 510(k) is for the addition of Trovafloxacin in the dilution range of 0.002 -- 4 ug/ml to the Sensititre 18 - 24 hour MIC panel for testing gram negative isolates.

Device Story

Sensititre 18-24 Hour Susceptibility Plates are in vitro diagnostic devices used in clinical laboratories to determine the minimum inhibitory concentration (MIC) or breakpoint susceptibility of bacteria. This submission adds the antibiotic Trovafloxacin to existing panels. The system utilizes microdilution plates containing specific concentrations of antimicrobial agents. Clinical isolates are inoculated into the wells; plates are incubated for 18-24 hours. Growth or inhibition is observed to determine susceptibility. Results assist clinicians in selecting appropriate antibiotic therapy for patients with bacterial infections. The device is intended for professional use in clinical laboratory settings.

Clinical Evidence

No clinical data provided. Substantial equivalence is based on bench testing of the antimicrobial susceptibility test panel performance.

Technological Characteristics

In vitro diagnostic microdilution susceptibility test panel. Consists of multi-well plates containing dehydrated antimicrobial agents (Trovafloxacin). Operates via broth microdilution method. Designed for use in clinical laboratory environments. No specific materials, energy sources, or software algorithms described in the provided text.

Indications for Use

Indicated for clinical susceptibility testing of gram-negative and gram-positive organisms. Specifically for testing gram-negative isolates against Trovafloxacin in the dilution range of 0.002–4 µg/ml.

Regulatory Classification

Identification

An antimicrobial susceptibility test powder is a device that consists of an antimicrobial drug powder packaged in vials in specified amounts and intended for use in clinical laboratories for determining in vitro susceptibility of bacterial pathogens to these therapeutic agents. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/2 description: The image is a black and white seal for the Department of Health & Human Services USA. The seal is circular with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" arranged around the perimeter. In the center of the seal is a stylized image of a caduceus, a symbol often associated with medicine and healthcare. The caduceus is depicted with a staff entwined by two snakes and topped with wings.

## NOV 2 5 1998

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Cynthia C. Knapp Director Lab Services AccuMed International, Inc. 29299 Clemens Road. Suite 1-K Westlake, OH 44145

Re: K983301 Trade Name: Sensititre 18-24 Hour Susceptibility Plates with Trovafloxacin Regulatory Class: II Product Code: JWY Dated: September 3, 1998 Received: September 21, 1998

Dear Ms. Knapp:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition. FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

{1}------------------------------------------------

## Page 2

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at [phone].

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number [phone] or at [phone] or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"

Sincerely yours,

Steven Butman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

510(k) Number (if known):

Jevice Name: Susceptibility Test Panel

Indications For Use:

The Sensititre 18 hour MIC or Breakpoint Susceptibility system is an in vitro diagnostic product for clinical susceptibility testing of gram negative and gram positive organisms.

This 510(k) is for the addition of Trovafloxacin in the dilution range of 0.002 -- 4 ug/ml to the Sensititre 18 - 24 hour MIC panel for testing gram negative isolates.

## (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Woody Dubois

Division Sign-Off) Division of Clinical Laboratory Devices K983301 510(k) Number _

Prescription Use
X
(Per 21 CFR 801.109)

OR

Over-The-Counter Use

(Optional Format 1-2-96)